According to a new report published by Introspective Market Research, titled, Personalized Genomics Market by Test Type, Application, and End User, The Global Personalized Genomics Market Size Was Valued at USD 3.25 Billion in 2023 and is Projected to Reach USD 5.72 Billion by 2032, Growing at a CAGR of 6.50%.The global personalized genomics market is experiencing steady growth as precision medicine continues to reshape modern healthcare. Personalized genomics involves analyzing an individual’s DNA to provide tailored insights into disease risk, drug response, and overall health management. Unlike traditional one-size-fits-all medical approaches, genomics-driven care enables healthcare providers to design more effective, individualized treatment and prevention strategies.
Growing consumer interest in wellness, ancestry testing, and predictive health is also fueling demand for direct-to-consumer genetic testing solutions. At the same time, healthcare institutions are integrating genomic insights into oncology, rare disease diagnostics, and pharmacogenomics. With continuous advancements in sequencing technologies and bioinformatics, the market is poised for sustainable expansion over the forecast period.
The Personalized Genomics Market is segmented into Test Type, Application, and End User.
-
By Test Type, the market is categorized into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others.
-
By Application, the market is categorized into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others.
-
By End User, the market is categorized into Hospitals & Clinics, Research Organizations, and Direct-to-Consumer.
One of the key growth drivers for the personalized genomics market is the increasing adoption of genetic testing for preventive healthcare. With rising awareness about hereditary diseases and lifestyle-related risks, individuals are turning to genomic testing to understand their predispositions and make informed health decisions. Governments and private entities are also investing heavily in genomics infrastructure, enabling broader accessibility and affordability of these services.
A major opportunity for market growth lies in the direct-to-consumer (DTC) genomics segment. As more people seek affordable, at-home genetic testing kits for ancestry, nutrition, and health insights, companies are expanding their consumer-friendly offerings. Emerging markets in Asia-Pacific and Latin America are particularly promising, given the rising middle-class population, growing digital healthcare penetration, and increased awareness of personalized wellness.
Detailed Segmentation
Personalized Genomics Market, Segmentation
The Personalized Genomics Market is segmented on the basis of Test Type, Application, and End User.
Test Type
The Test Type segment is further classified into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others. Among these, the Whole Genome Sequencing sub-segment accounted for the highest market share in 2023. Its popularity is driven by its ability to provide comprehensive genetic information, supporting applications in disease prevention, precision oncology, and lifestyle management. Increasing affordability and wider clinical adoption continue to strengthen this sub-segment’s dominance.
Application
The Application segment is further classified into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others. Among these, the Oncology sub-segment accounted for the highest market share in 2023. Genomic profiling plays a crucial role in identifying tumor mutations and guiding targeted therapies, which is transforming cancer treatment outcomes. Rising cancer prevalence and increased research collaborations further support the growth of this segment.
Some of The Leading/Active Market Players Are-
- Illumina, Inc. (USA)
- Thermo Fisher Scientific Inc. (USA)
- F. Hoffmann-La Roche AG (Switzerland)
- BGI Genomics Co., Ltd. (China)
- 23andMe, Inc. (USA)
- Myriad Genetics, Inc. (USA)
- Gene by Gene, Ltd. (USA)
- Color Health, Inc. (USA)
- Dante Labs (Italy)
- QIAGEN N.V. (Netherlands/Germany)
- Nebula Genomics (USA)
- Veritas Genetics (USA)
- Mapmygenome India Ltd. (India)
- Oxford Nanopore Technologies plc (UK)
- Invitae Corporation (USA)
- other active players.
Key Industry Developments
- In February 2024, Thermo Fisher Scientific expanded its genetic testing portfolio with advanced sequencing platforms designed for clinical and research applications.
This innovation aims to accelerate adoption in hospitals and research institutions by offering faster, more accurate genomic analysis. - In September 2024, 23andMe launched an upgraded ancestry and health insights kit, integrating AI-based interpretation tools.
The launch is expected to expand consumer adoption of direct-to-consumer genomics by offering deeper insights at more affordable pricing.
Key Findings of the Study
- Whole Genome Sequencing dominated the test type segment in 2023.
- Oncology was the leading application segment.
- North America accounted for the largest revenue share.
- Preventive healthcare adoption is a primary growth driver.
- Direct-to-consumer genomics presents strong opportunities in emerging regions.
